aTyr Pharma Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sanjay Shukla

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	43.2%
Permanencia del CEO	7yrs
Participación del CEO	0.2%
Permanencia media de la dirección	5.9yrs
Promedio de permanencia en la Junta Directiva	15.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sanjay Shukla en comparación con los beneficios de aTyr Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$64m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$1m	US$561k	-US$50m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$45m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$561k	-US$45m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$41m
Mar 31 2022	n/a	n/a	-US$39m
Dec 31 2021	US$2m	US$510k	-US$34m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$25m
Dec 31 2020	US$1m	US$470k	-US$16m
Sep 30 2020	n/a	n/a	-US$17m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$664k	US$450k	-US$24m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$30m
Dec 31 2018	US$1m	US$450k	-US$35m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$45m
Dec 31 2017	US$2m	US$403k	-US$48m

Compensación vs. Mercado: La compensación total de Sanjay($USD1.30M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD787.21K).

Compensación vs. Ingresos: La compensación de Sanjay ha sido consistente con los resultados de la empresa en el último año.

CEO

Sanjay Shukla (52 yo)

7yrs

Permanencia

US$1,300,525

Compensación

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sanjay Shukla	President	7yrs	US$1.30m	0.16% € 425.2k
Jill Broadfoot	Chief Financial Officer	6.3yrs	US$677.84k	0.025% € 64.8k
Nancy E. Krueger	General Counsel & Corporate Secretary	10.1yrs	US$651.28k	0.027% € 69.3k
Xiang-Lei Yang	Founder	no data	sin datos	sin datos
Jayant Aphale	Vice President of Technical Operations	less than a year	sin datos	sin datos
Ashlee Dunston	Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Peter Villiger	Vice President of Corporate Development	4.8yrs	sin datos	sin datos
Danielle Campbell	VP of Human Resource	2.9yrs	sin datos	sin datos
Leslie Nangle	Vice President of Research	no data	sin datos	sin datos
Ying Buechler	Executive Director of Biologics Development & Manufacturing	no data	sin datos	sin datos
David King	Scientific Consultant	5.9yrs	US$717.31k	sin datos

5.9yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 471A es experimentado (5.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sanjay Shukla	President	7yrs	US$1.30m	0.16% € 425.2k
John Clarke	Independent Director	19.2yrs	US$120.84k	0.024% € 61.6k
Paul Schimmel	Independent Director	19.2yrs	US$61.20k	1.31% € 3.4m
Floyd Bloom	Member of Scientific Advisory Board	15.1yrs	sin datos	sin datos
Bruce Beutler	Member of Scientific Advisory Board	15.3yrs	sin datos	sin datos
Benjamin Cravatt	Member of Scientific Advisory Board	no data	sin datos	sin datos
Timothy Coughlin	Independent Chairman of the Board	7.6yrs	US$92.20k	0.067% € 174.4k
Osamu Nureki	Member of Scientific Advisory Board	15.2yrs	sin datos	sin datos
Susan Ackerman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Wing Wong	Member of Scientific Advisory Board	no data	sin datos	sin datos
Nancy Ip	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jane Gross	Independent Director	5.3yrs	US$68.88k	0.0072% € 18.7k

15.1yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 471A son experimentados ( 15.1 años antigüedad media).

aTyr Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently bought €170k worth of stock

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Independent Director recently bought €410k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Profitability

Independent Director recently bought €170k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

New major risk - Share price stability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Independent Director recently bought €410k worth of stock

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Independent Director recently bought €163k worth of stock

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

New 90-day high: €6.35

aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC

aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad